ArticleMolecular genetics and metabolism reports2022

A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation.

Shiri Curelaru et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.